PROCEPT BioRobotics Corporation $PRCT Shares Purchased by Mitsubishi UFJ Asset Management Co. Ltd.

Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) by 109.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 159,874 shares of the company’s stock after buying an additional 83,498 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. owned 0.29% of PROCEPT BioRobotics worth $9,209,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in PRCT. Alliancebernstein L.P. boosted its position in PROCEPT BioRobotics by 22.3% during the 1st quarter. Alliancebernstein L.P. now owns 2,143,693 shares of the company’s stock worth $124,892,000 after acquiring an additional 391,215 shares during the period. T. Rowe Price Investment Management Inc. lifted its position in PROCEPT BioRobotics by 43.6% in the first quarter. T. Rowe Price Investment Management Inc. now owns 1,415,403 shares of the company’s stock worth $82,462,000 after purchasing an additional 429,461 shares during the period. Price T Rowe Associates Inc. MD raised its stake in shares of PROCEPT BioRobotics by 47.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,055,762 shares of the company’s stock worth $61,510,000 after buying an additional 341,906 shares in the last quarter. Westfield Capital Management Co. LP boosted its stake in PROCEPT BioRobotics by 43.2% during the first quarter. Westfield Capital Management Co. LP now owns 748,557 shares of the company’s stock valued at $43,611,000 after buying an additional 225,894 shares in the last quarter. Finally, Champlain Investment Partners LLC raised its position in PROCEPT BioRobotics by 48.0% in the first quarter. Champlain Investment Partners LLC now owns 676,196 shares of the company’s stock worth $39,395,000 after acquiring an additional 219,266 shares in the last quarter. Institutional investors own 89.46% of the company’s stock.

PROCEPT BioRobotics Price Performance

Shares of PRCT opened at $30.77 on Thursday. The company has a debt-to-equity ratio of 0.14, a current ratio of 8.44 and a quick ratio of 7.20. The company has a market capitalization of $1.72 billion, a price-to-earnings ratio of -20.11 and a beta of 0.98. The business’s 50-day moving average is $35.53 and its 200-day moving average is $47.15. PROCEPT BioRobotics Corporation has a fifty-two week low of $29.78 and a fifty-two week high of $100.89.

PROCEPT BioRobotics (NASDAQ:PRCT) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.03. PROCEPT BioRobotics had a negative net margin of 28.20% and a negative return on equity of 21.72%. The firm had revenue of $83.33 million for the quarter, compared to the consensus estimate of $80.78 million. During the same period in the previous year, the firm posted ($0.40) earnings per share. The firm’s revenue was up 42.6% on a year-over-year basis. PROCEPT BioRobotics has set its FY 2026 guidance at EPS. FY 2025 guidance at EPS. Equities research analysts expect that PROCEPT BioRobotics Corporation will post -1.75 EPS for the current fiscal year.

Wall Street Analyst Weigh In

PRCT has been the subject of several recent research reports. Leerink Partners reissued an “outperform” rating and set a $55.00 target price on shares of PROCEPT BioRobotics in a research note on Wednesday, November 5th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PROCEPT BioRobotics in a research note on Wednesday, October 8th. Piper Sandler reissued an “overweight” rating and issued a $50.00 target price (down from $55.00) on shares of PROCEPT BioRobotics in a research report on Wednesday, November 5th. BTIG Research restated a “neutral” rating on shares of PROCEPT BioRobotics in a report on Tuesday, September 16th. Finally, Wells Fargo & Company cut their price target on shares of PROCEPT BioRobotics from $58.00 to $51.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. Nine research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, PROCEPT BioRobotics presently has an average rating of “Moderate Buy” and a consensus price target of $63.30.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).